120 related articles for article (PubMed ID: 31663414)
21. The impact of socioeconomic status on stage specific prostate cancer survival and mortality before and after introduction of PSA test in Finland.
Seikkula HA; Kaipia AJ; Ryynänen H; Seppä K; Pitkäniemi JM; Malila NK; Boström PJ
Int J Cancer; 2018 Mar; 142(5):891-898. PubMed ID: 29044563
[TBL] [Abstract][Full Text] [Related]
22. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
23. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy.
D'Amico AV; Renshaw AA; Sussman B; Chen MH
JAMA; 2005 Jul; 294(4):440-7. PubMed ID: 16046650
[TBL] [Abstract][Full Text] [Related]
24. Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.
Hugosson J; Godtman RA; Carlsson SV; Aus G; Grenabo Bergdahl A; Lodding P; Pihl CG; Stranne J; Holmberg E; Lilja H
Scand J Urol; 2018 Feb; 52(1):27-37. PubMed ID: 29254399
[TBL] [Abstract][Full Text] [Related]
25. Effects of an Educational Program for Prostate Cancer Prevention on knowledge and PSA Testing in Men Over 50 Years old in Community Areas of Shiraz in 2016.
Molazem Z; Ebadi M; Khademian M; Zare R
Asian Pac J Cancer Prev; 2018 Mar; 19(3):633-637. PubMed ID: 29580031
[TBL] [Abstract][Full Text] [Related]
26. Socioeconomic variation and prostate specific antigen testing in the community: a United Kingdom based population study.
Morgan RM; Steele RJ; Nabi G; McCowan C
J Urol; 2013 Oct; 190(4):1207-12. PubMed ID: 23608675
[TBL] [Abstract][Full Text] [Related]
27. Correlates of prostate-specific antigen testing in a large multiethnic cohort.
Haque R; Van Den Eeden SK; Jacobsen SJ; Caan B; Avila CC; Slezak J; Sternfeld B; Loo RK; Quinn VP
Am J Manag Care; 2009 Nov; 15(11):793-9. PubMed ID: 19895183
[TBL] [Abstract][Full Text] [Related]
28. [Advantages and risks of the use of prostate-specific antigen (PSA) in the health-care area No. 4 of Gijon (Asturias)].
Cepeda Piorno J; Rivas del Fresno M; Fuente Martín E; González García E; Muruamendiaraz Fernández V; Fernández Rodríguez E
Arch Esp Urol; 2005 Jun; 58(5):403-11. PubMed ID: 16078781
[TBL] [Abstract][Full Text] [Related]
29. Rural-Urban Differences in Prostate-Specific Antigen (PSA) Screening and Its Outcomes in New Zealand.
Obertová Z; Hodgson F; Scott-Jones J; Brown C; Lawrenson R
J Rural Health; 2016; 32(1):56-62. PubMed ID: 26174590
[TBL] [Abstract][Full Text] [Related]
30. High rates of prostate-specific antigen testing in men with evidence of benign prostatic hyperplasia.
Meigs JB; Barry MJ; Giovannucci E; Rimm EB; Stampfer MJ; Kawachi I
Am J Med; 1998 Jun; 104(6):517-25. PubMed ID: 9674713
[TBL] [Abstract][Full Text] [Related]
31. Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics.
Negoita S; Feuer EJ; Mariotto A; Cronin KA; Petkov VI; Hussey SK; Benard V; Henley SJ; Anderson RN; Fedewa S; Sherman RL; Kohler BA; Dearmon BJ; Lake AJ; Ma J; Richardson LC; Jemal A; Penberthy L
Cancer; 2018 Jul; 124(13):2801-2814. PubMed ID: 29786851
[TBL] [Abstract][Full Text] [Related]
32. Impact of Accountable Care Organizations on Diagnostic Testing for Prostate Cancer.
Luckenbaugh AN; Hollenbeck BK; Kaufman SR; Yan P; Herrel LA; Skolarus TA; Norton EC; Schroeck FR; Jacobs BL; Miller DC; Hollingsworth JM; Shahinian VB; Borza T
Urology; 2018 Jun; 116():68-75. PubMed ID: 29630957
[TBL] [Abstract][Full Text] [Related]
33. Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer.
Bunting PS; Goel V; Williams JI; Iscoe NA
CMAJ; 1999 Jan; 160(1):70-5. PubMed ID: 9934349
[TBL] [Abstract][Full Text] [Related]
34. The impact of sociodemographic factors and PSA screening among low-income Black and White men: data from the Southern Community Cohort Study.
Moses KA; Zhao Z; Bi Y; Acquaye J; Holmes A; Blot WJ; Fowke JH
Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):424-429. PubMed ID: 28695916
[TBL] [Abstract][Full Text] [Related]
35. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
Kelly SP; Anderson WF; Rosenberg PS; Cook MB
Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
[TBL] [Abstract][Full Text] [Related]
36. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011.
Nordström T; Aly M; Clements MS; Weibull CE; Adolfsson J; Grönberg H
Eur Urol; 2013 Mar; 63(3):419-25. PubMed ID: 23083803
[TBL] [Abstract][Full Text] [Related]
37. Do Men Receive Information Required for Shared Decision Making About PSA Testing? Results from a National Survey.
Leyva B; Persoskie A; Ottenbacher A; Hamilton JG; Allen JD; Kobrin SC; Taplin SH
J Cancer Educ; 2016 Dec; 31(4):693-701. PubMed ID: 26498649
[TBL] [Abstract][Full Text] [Related]
38. PSA testing for prostate cancer: an online survey of the views and reported practice of General Practitioners in the UK.
Brett J; Watson E; Hewitson P; Bukach C; Edwards A; Elwyn G; Austoker J
BMC Fam Pract; 2005 Jun; 6(1):24. PubMed ID: 15946386
[TBL] [Abstract][Full Text] [Related]
39. Factors influencing use of the prostate-specific antigen screening test in primary care.
Moran WP; Cohen SJ; Preisser JS; Wofford JL; Shelton BJ; McClatchey MW
Am J Manag Care; 2000 Mar; 6(3):315-24. PubMed ID: 10977432
[TBL] [Abstract][Full Text] [Related]
40. Factors influencing primary care physicians' decision to order prostate-specific antigen (PSA) test for men without prostate cancer.
Hayat Roshanai A; Nordin K; Berglund G
Acta Oncol; 2013 Nov; 52(8):1602-8. PubMed ID: 23421929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]